UBS Group AG decreased its position in shares of Geron Corporation (NASDAQ:GERN – Free Report) by 57.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,273,705 shares of the biopharmaceutical company’s stock after selling 4,447,402 shares during the period. UBS Group AG’s holdings in Geron were worth $4,321,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Candriam S.C.A. lifted its stake in Geron by 71.6% during the 3rd quarter. Candriam S.C.A. now owns 3,253,960 shares of the biopharmaceutical company’s stock worth $4,458,000 after acquiring an additional 1,358,068 shares in the last quarter. Almitas Capital LLC acquired a new position in Geron during the 3rd quarter worth about $1,296,000. Aberdeen Group plc raised its position in Geron by 59.6% in the 4th quarter. Aberdeen Group plc now owns 9,527,083 shares of the biopharmaceutical company’s stock valued at $12,576,000 after purchasing an additional 3,556,160 shares in the last quarter. Vanguard Group Inc. raised its position in Geron by 3.6% in the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock valued at $47,072,000 after purchasing an additional 1,237,844 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its position in Geron by 15.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 421,458 shares of the biopharmaceutical company’s stock valued at $556,000 after purchasing an additional 57,058 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.
Wall Street Analyst Weigh In
GERN has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Monday, April 27th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research report on Thursday, January 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.50.
Geron Price Performance
GERN stock opened at $1.28 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. The firm has a market capitalization of $821.15 million, a P/E ratio of -11.64 and a beta of 0.68. The business’s 50-day moving average is $1.53 and its two-hundred day moving average is $1.44. Geron Corporation has a 1 year low of $1.04 and a 1 year high of $2.01.
Geron (NASDAQ:GERN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $51.84 million for the quarter, compared to analyst estimates of $50.59 million. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%. Analysts anticipate that Geron Corporation will post -0.02 earnings per share for the current fiscal year.
Geron Company Profile
Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.
The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.
See Also
- Five stocks we like better than Geron
- MarketBeat Week in Review – 05/18 – 05/22
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Corporation (NASDAQ:GERN – Free Report).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
